利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

48 条记录 (耗时 0.026 秒)

    Novel nucleic acids and polypeptides related to a guanine exchange factor of Rho GTPase
    1.
    发明申请
    Novel nucleic acids and polypeptides related to a guanine exchange factor of Rho GTPase 失效
    与Rho GTP酶的鸟嘌呤交换因子相关的新型核酸和多肽

    公开(公告)号：US20070161021A1

    公开(公告)日：2007-07-12

    申请号：US11603491

    申请日：2006-11-22

    申请人： Matthew Hart

    发明人： Matthew Hart

    IPC分类号： C12Q1/68 ,  C07H21/04 ,  C12P21/06 ,  C12N9/22 ,  C07K14/705 ,  A61K48/00

    CPC分类号： C07K16/18 ,  A61K38/00 ,  A61K48/00 ,  C07K14/82 ,  C12Q1/6876

    摘要： The present invention relates to all aspects of a guanine exchange factor (GEF), for example, a Rho-GEF, such as p115 Rho-GEF. A GEF modulates cell signaling pathways, both in in vitro and in vivo, by modulating the activity of a GTPase. By way of illustration, a p115 Rho-GEF, which modulates the activity of a Rho GTPase, is described. However, the present invention relates to other GEFs, especially other Rho-GEFs. The present invention particularly relates to an isolated p115 Rho-GEF polypeptide or fragments of it, a nucleic acid coding for p115 Rho-GEF or fragments of it, and derivatives of the polypeptide and nucleic acid. The invention also relates to methods of using such polypeptides, nucleic acids, or derivatives thereof, e.g., in therapeutics, diagnostics, and as research tools. Another aspect of the present invention involves antibodies and other ligands which recognize p115 Rho-GEF, regulators of p115 Rho-GEF activity, and methods of treating pathological conditions associated or related to a Rho GTPase.

    摘要翻译： 本发明涉及鸟嘌呤交换因子（GEF），例如Rho-GEF，例如p15Rho-GEF的所有方面。 通过调节GTP酶的活性，GEF在体外和体内调节细胞信号通路。 作为说明，描述了调节Rho GTP酶的活性的p115Rho-GEF。 然而，本发明涉及其他GEF，特别是其他Rho-GEF。 本发明特别涉及分离的p115Rho-GEF多肽或其片段，编码p115Rho-GEF或其片段的核酸，以及多肽和核酸的衍生物。 本发明还涉及使用此类多肽，核酸或其衍生物的方法，例如在治疗学，诊断学和研究工具中。 本发明的另一方面涉及识别p115Rho-GEF，p115Rho-GEF活性的调节剂以及治疗与Rho GTP酶相关或相关的病理学病症的方法的抗体和其它配体。

    Method for purifying virus
    3.
    发明申请
    Method for purifying virus 审中-公开
    病毒纯化方法

    公开(公告)号：US20050003507A1

    公开(公告)日：2005-01-06

    申请号：US10869143

    申请日：2004-06-16

    申请人： Paul Kostel ,  Kurt Yanagimachi ,  Charles Olson

    发明人： Paul Kostel ,  Kurt Yanagimachi ,  Charles Olson

    IPC分类号： A61K20060101 ,  C12N7/02

    CPC分类号： C12N7/00 ,  C12N2710/10351

    摘要： A process for the purification of viruses from a cell lysate preparation is described, consisting of preferably two successive chromatographic steps; the first a clarification step utilizing size exclusion chromatography, and the second, a virus capture and release step using anion exchange chromatography, which successive chromatographic steps have the advantage of purifying virus, and avoiding chromatography buffer conductivity adjustments.

    摘要翻译： 描述了从细胞裂解物制剂中纯化病毒的方法，其优选包括两个连续的色谱步骤; 第一个使用尺寸排阻色谱的澄清步骤，第二个是使用阴离子交换色谱法的病毒捕获和释放步骤，其连续的色谱步骤具有净化病毒的优点，并避免色谱缓冲液电导率调节。

    Cytopathic viruses for therapy and prophylaxis of neoplasia
    6.
    发明授权
    Cytopathic viruses for therapy and prophylaxis of neoplasia 失效
    用于治疗和预防肿瘤的细胞病变病毒

    公开(公告)号：US5677178A

    公开(公告)日：1997-10-14

    申请号：US641081

    申请日：1996-04-29

    申请人： Francis McCormick

    发明人： Francis McCormick

    IPC分类号： A61K35/76 ,  A61K35/761 ,  A61K48/00 ,  C12N7/00 ,  C12N7/04 ,  C12N15/861 ,  C12N5/10 ,  C12N7/01 ,  C07H21/04

    CPC分类号： C12N15/86 ,  A61K35/761 ,  C12N7/00 ,  A61K48/00 ,  C12N2710/10321 ,  C12N2710/10332 ,  C12N2710/10343 ,  C12N2710/10362

    摘要： Methods and compositions for treating neoplastic conditions by viral-based therapy are provided. Mutant virus lacking viral proteins which bind and/or inactivate p53 or RB are administered to a patient having a neoplasm which comprises cells lacking p53 and/or RB function. The mutant virus is able to substantially produce a replication phenotype in neoplastic cells but is substantially unable to produce a replication phenotype in non-replicating, non-neoplastic cells having essentially normal p53 and/or RB function. The preferential generation of replication phenotype in neoplastic cells results in a preferential killing of the neoplastic cells, either directly or by expression of a cytotoxic gene in cells expressing a viral replication phenotype.

    摘要翻译： 提供了通过病毒治疗来治疗肿瘤病症的方法和组合物。 将具有结合和/或失活p53或RB的病毒蛋白的突变病毒给予具有肿瘤的患者，所述肿瘤包含缺乏p53和/或RB功能的细胞。 突变型病毒能够在肿瘤细胞中基本上产生复制表型，但基本上不能在具有基本正常p53和/或RB功能的非复制性非肿瘤细胞中产生复制表型。 在肿瘤细胞中优先产生复制表型导致直接或通过在表达病毒复制表型的细胞中表达细胞毒性基因来赘生性细胞的优先杀伤。

    Adenoviral vectors for treating disease
    8.
    发明授权
    Adenoviral vectors for treating disease 失效
    用于治疗疾病的腺病毒载体

    公开(公告)号：US07829329B2

    公开(公告)日：2010-11-09

    申请号：US10306275

    申请日：2002-11-27

    申请人： Terry Hermiston ,  Lynda K. Hawkins ,  Leisa Johnson

    发明人： Terry Hermiston ,  Lynda K. Hawkins ,  Leisa Johnson

    IPC分类号： C12N15/00 ,  C12N7/00 ,  A01N43/04

    CPC分类号： C12N15/86 ,  A61K35/761 ,  A61K38/1761 ,  A61K38/191 ,  A61K38/195 ,  A61K38/20 ,  A61K38/217 ,  A61K48/00 ,  C12N2710/10332 ,  C12N2710/10343

    摘要： Adenoviral vectors, including mutant adenoviruses, that have restriction sites in the E3 region, that facilitate its partial or total deletion, or select genes contained therein, and optionally compositions and methods for substituting heterologous gene(s) in the partially or totally deleted E3 region(s), which heterologous gene(s) being operably linked to endogenous adenoviral transcriptional control sequences will exhibit an expression pattern, both in terms of timing and degree of expression, similar to the endogenous adenoviral gene(s) that it replaces, and further optionally including mutations in other parts of the adenoviral genome, including certain E1B or E1A regions, and that have applications for diagnosing or treating disease, preferably disease involving unwanted cell growth, including cancer.

    摘要翻译： 在E3区域具有限制性位点，促进其部分或全部缺失的腺病毒载体，或其中所含的选择基因的任何组合物和方法，以及在部分或全部缺失的E3区域中取代异源基因的组合物和方法 其异源基因与内源性腺病毒转录控制序列可操作地连接将在时间和表达程度方面表现出类似于其所取代的内源性腺病毒基因的表达模式，并且进一步 任选地包括在腺病毒基因组的其他部分中的突变，包括某些E1B或E1A区域，并且具有用于诊断或治疗疾病，优选涉及不想要的细胞生长的疾病（包括癌症）的应用。

    Human PAK65
    9.
    发明授权
    Human PAK65 失效
    人类PAK65

    公开(公告)号：US6048706A

    公开(公告)日：2000-04-11

    申请号：US108262

    申请日：1998-07-01

    申请人： Arie Abo ,  George A. Martin

    发明人： Arie Abo ,  George A. Martin

    IPC分类号： B60R9/042 ,  C12N9/12 ,  C12Q1/48 ,  C12N5/00 ,  G01N33/53

    CPC分类号： C12N9/1205 ,  B60R9/042

    摘要： A novel human serine protein kinase, human p21-protein activated serine kinase p65 protein, referred to as hPAK65, and methods for its preparation and use are provided. Nucleic acids encoding hPAK65 and methods for their use in preparing hPAK65 as well as in preparing and identifying hPAK65 analogs are provided. Methods provided for the use of hPAK65 protein and its protein fragments, such as those that retain at least one hPAK65 activity, that include screening libraries of agents for candidates that modulate hPAK65 activity. Methods are provided to identify agents that modulate the interaction of hPAK65 with rho-like p21 GTPases, particularly rac1 and CDC42Hs binding to hPAK65 and subsequent activation of hPAK65 serine protein kinase activity, that modulate hPAK65 serine protein kinase activity, and that modulate hPAK65 effect on p21 protein GTPase activity. Such modulating agents can provide novel chemotherapeutic agents for treatment of neoplasia, lymphoproliferative conditions, arthritis, inflammation, autoimmune diseases, apoptosis, and the like, that are related to hPAK65 and p21 protein signal transduction pathways.

    摘要翻译： 提供了一种新的人丝氨酸蛋白激酶，人p21蛋白激活的丝氨酸激酶p65蛋白，被称为hPAK65，以及其制备和使用方法。 提供编码hPAK65的核酸及其制备hPAK65以及制备和鉴定hPAK65类似物的方法。 提供使用hPAK65蛋白及其蛋白质片段（例如保留至少一种hPAK65活性的蛋白质片段）的方法，包括筛选调节hPAK65活性的候选物的试剂库。 提供方法来鉴定调节hPAK65与rho样p21GTP酶，特别是结合hPAK65的rac1和CDC42H以及随后激活hPAK65丝氨酸蛋白激酶活性的调节hPAK65丝氨酸蛋白激酶活性的相互作用的试剂，并调节hPAK65对hPAK65的影响 p21蛋白GTPase活性。 这些调节剂可以提供用于治疗与hPAK65和p21蛋白信号转导途径有关的肿瘤形成，淋巴组织增生病症，关节炎，炎症，自身免疫性疾病，凋亡等的新型化学治疗剂。

    Human PAK65
    10.
    发明授权
    Human PAK65 失效
    人类PAK65

    公开(公告)号：US06013464A

    公开(公告)日：2000-01-11

    申请号：US918509

    申请日：1997-08-22

    申请人： Arie Abo ,  George A. Martin

    发明人： Arie Abo ,  George A. Martin

    IPC分类号： G01N33/566 ,  A61K31/70 ,  A61K38/55 ,  A61P25/00 ,  A61P29/00 ,  A61P35/02 ,  A61P37/00 ,  C12N5/10 ,  C12N9/12 ,  C12N15/09 ,  C12P21/04 ,  G01N33/15 ,  C12Q1/48 ,  C12Q1/00 ,  G01N33/53

    CPC分类号： C12N9/1205

    摘要： A novel human serine protein kinase, human p21-protein activated serine kinase p65 protein, referred to as hPAK65, and methods for its preparation and use are provided. Nucleic acids encoding hPAK65 and methods for their use in preparing hPAK65 as well as in preparing and identifying hPAK65 analogs are provided. Methods provided for the use of hPAK65 protein and its protein fragments, such as those that retain at least one hPAK65 activity, that include screening libraries of agents for candidates that modulate hPAK65 activity. Methods are provided to identify agents that modulate the interaction of hPAK65 with rho-like p21 GTPases, particularly rac 1 and CDC42Hs binding to hPAK65 and subsequent activation of hPAK65 serine protein kinase activity, that modulate hPAK65 serine protein kinase activity, and that modulate hPAK65 effect on p21 protein GTPase activity. Such modulating agents can provide novel chemotherapeutic agents for treatment of neoplasia, lymphoproliferative conditions, arthritis, inflammation, autoimmune diseases, apoptosis, and the like, that are related to hPAK65 and p21 protein signal transduction pathways.

    摘要翻译： 提供了一种新的人丝氨酸蛋白激酶，人p21蛋白激活的丝氨酸激酶p65蛋白，被称为hPAK65，以及其制备和使用方法。 提供编码hPAK65的核酸及其制备hPAK65以及制备和鉴定hPAK65类似物的方法。 提供使用hPAK65蛋白及其蛋白质片段（例如保留至少一种hPAK65活性的蛋白质片段）的方法，包括筛选调节hPAK65活性的候选物的试剂库。 提供了用于鉴定调节hPAK65与rho样p21 GTP酶，特别是结合hPAK65的外消旋1和CDC42Hs以及随后激活hPAK65丝氨酸蛋白激酶活性，调节hPAK65丝氨酸蛋白激酶活性并调节hPAK65效应的相互作用的试剂 对p21蛋白的GTPase活性。 这些调节剂可以提供用于治疗与hPAK65和p21蛋白信号转导途径有关的肿瘤形成，淋巴组织增生病症，关节炎，炎症，自身免疫性疾病，凋亡等的新型化学治疗剂。